BioRestorative Therapies Offers $ 23 Million Public Offering

Common shares will begin trading on the Nasdaq Capital Market under the ticker symbol “BRTX” on November 5, 2021

MELVILLE, NY, November 04, 2021 (GLOBE NEWSWIRE) – BioRestorative Therapies, Inc. (the “Company”) (NASDAQ: BRTX), a life sciences company focused on adult stem cell therapies, has announced today the price of the subscribed public offering of 2,300,000 units, each consisting of one share of its common shares and a warrant to purchase one share of its common shares at a unit price of $ 10.00. The warrants have an exercise price per share of $ 10.00, are exercisable immediately, and expire five years from the date of issue. Total gross proceeds from the offering are expected to total $ 23 million, before deducting any discounts and subscription commissions and estimated offering fees payable by the Company and without taking into account the proceeds from any subsequent exercise of mandates.

Following the offer, the common shares of the Company will be listed on the Nasdaq Capital Market and will trade under the ticker symbol “BRTX” as of November 5, 2021. The offer is expected to close on or around November 9. 2021, subject to customary closing conditions. In addition, the Company has granted the underwriters of the offering a 45-day option to purchase up to 345,000 additional shares and / or additional warrants to purchase up to 345,000 common shares to cover the over-allotments, the optionally.

Roth Capital Partners acts as the sole manager of the offer.

“BioRestorative Therapies’ advancement into the Nasdaq capital market continues a year of growth and accomplishments for our business in which we emerged from the Chapter 11 reorganization, transformed our business, strengthened our financial position and improved our position on intellectual property, ”said Lance Alstodt, President and CEO of BioRestorative.

The securities described above are sold by BioRestorative Therapies in accordance with a registration statement on Form S-1 (registration number 333-258611) that has been previously filed by BioRestorative Therapies with the Securities and Exchange Commission (the “SEC”) and declared effective on November 4, 2021 and an additional registration statement filed in accordance with Rule 462 (b), which came into effect on filing. This press release does not constitute an offer to sell or the solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal before registration. or qualification under the securities laws of any such state or jurisdiction.

The offer is made only by means of the written prospectus forming part of the actual registration statement. Electronic copies of the attached prospectus may be obtained, when available, by contacting Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or by mail electronically at [email protected], or by visiting the SEC website at

About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ( develops therapeutic products using cellular and tissue protocols, primarily involving adult stem cells. Our two main programs, described below, relate to the treatment of disc / spinal disease and metabolic disorders:

• Disc / Spine program (brtxDISCâ„¢): Our main candidate in cell therapy, BRTX-100, is a product formulated from autologous (or personal) mesenchymal stem cells taken from the patient’s bone marrow. We intend the product to be used for the non-surgical treatment of painful lumbosacral disc disorders or as an adjunct therapy to surgery. The BRTX-100 The production process uses proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 must be injected by a doctor into the damaged disc of the patient. Treatment is for patients whose pain has not been relieved by non-invasive procedures and who are potentially facing the prospect of surgery. We have received approval from the Food and Drug Administration to begin a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain caused by degenerative disc disease.

• Metabolic program (ThermoStem®): We are developing a cell therapy candidate to target obesity and metabolic disorders using brown fat derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic the natural brown fat deposits that regulate metabolic homeostasis in humans. Early preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional calorie burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk of obesity and diabetes.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made in accordance the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that these statements are subject to a multitude of risks and uncertainties which could cause materially different circumstances, events or future results.y those projected in forward-looking statements due to various factors and other risks, including, without limitation, those set forth in the Company’s latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included in this document, and do not place undue reliance on such statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company does not undertake to update thesuch statements.


Email: [email protected]

Comments are closed.